Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015
Electron microscopic image of a single human lymphocyte. Credit: Dr. Triche National Cancer Institute

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' response to immunotherapy drugs. An increasingly promising focus of cancer research, the drugs are designed to disarm cancer cells' ability to avoid detection and destruction by the immune system.

In a report on the work published in the Aug. 27 issue of Cell, the Johns Hopkins-led research team says it has found a core group of genes related to both a viral defense warning system and susceptibility to a demethylating drug called 5-azacytidine that chemically alters their ability to operate through a process called demethylation.

A study with similar findings authored by Daniel De Carvalho, Ph.D., at the Ontario Cancer Institute/Princess Margaret Hospital, and Peter Jones, Ph.D., D.Sc., director of research at the Van Andel Institute, focused on the ability of DNA demethylating agents to target colorectal , is published in the same journal issue.

Tumors are known to co-opt cellular gene-silencing systems that add tiny chemicals called methyl groups to areas of genes, thereby turning off the affected gene function. Such "epigenetic" control normally occurs in many genes, including ones that contain DNA leftover from previous exposures to viruses. When epigenetic control of these genes is removed, the virus-laden gene sequences are activated and trigger an alert to that a virus has invaded.

"A main barrier to success has been the tumor's ability to keep the from functioning against the ," says study leader Stephen Baylin, M.D., the Virginia and Daniel K. Ludwig Professor of Cancer Research at the Kimmel Cancer Center. "The are there, but like an unarmed army, they hang around and do nothing. However, certain epigenetic processes that silence such viral defense genes can be reversed in tumor with a demethylating drug, making immunotherapies work more effectively to kill ."

For their new study, Baylin and his team worked with laboratory-grown cell lines from human ovarian, colon and skin cancer, and the team led by De Carvalho worked with . In the cancer cell lines, both teams found that the viral defense pathway can be turned on when the cells were exposed to 5-azacytidine. Once the pathway is activated, Baylin adds, the tumor cells release signaling proteins called interferons that rouse other cancer-fighting cells in the immune system.

Then, the Johns Hopkins team created a gene signature of the viral defense pathway. In tumor samples available from the National Cancer Institute's Cancer Genome Atlas project, the scientists used the gene signature to distinguish between tumor samples with high expression of the pathway from those with low expression. Those with high expression may respond to certain immunotherapy drugs without the aid of 5-azacytidine, but those with low expression levels may need the epigenetic drug to boost response to immunotherapy, says Baylin.

Looking for the connection between the pathway's expression and immunotherapy drug response, the Johns Hopkins investigators and their colleagues focused on expression levels of the viral defense pathway in tumor cells from 21 patients with melanoma treated with the immune therapy drug ipilimumab at Memorial Sloan Kettering Cancer Center. They found high expression levels in the cells of seven of eight of those patients who had responded well to ipilimumab. Cells from all 12 patients with limited response to ipilimumab had low expression of the viral defense pathway.

In a melanoma mouse model in which ipilimumab alone was partially effective, adding 5-azacytidine to ipilimumab triggered a better tumor response.

"Our findings further decipher the mechanisms that lead to this tumor cell immune reaction and offer a way to potentially boost the success of immune therapies in patients with cancer," says Baylin, who first became interested in the immune system's connection to 5-azacytidine when laboratory research and clinical trials at Johns Hopkins hinted at the drug's ability to prevent cancer cells' proliferation when combined with immunotherapy.

Baylin and his colleagues say that, if their findings are confirmed and extended in clinical trials, the 5-azacytidine treatment could be followed by ipilimumab or other types of immunotherapy called checkpoint blockade, which lower cancer cells' defenses and allow immune system cells to see and destroy them.

"Treatment with 5-azacytidine activates interferon signaling in and, when followed by checkpoint blockade immune therapy, the immune cells could go into increased action against the cancer," says Johns Hopkins research fellow and lead author Katherine Chiappinelli, Ph.D.

Baylin and Chiappinelli caution that clinical trials will take time to learn how effective the strategy of alerting the viral defense pathway might be. But the strategy holds promise, he says, for patients who have cancers with low expression of the pathway.

Explore further: Protein FGL2 may have potential as therapy target for brain cancer

Related Stories

Protein FGL2 may have potential as therapy target for brain cancer

May 13, 2015
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.

Study adds to cancer-fighting promise of combined immunotherapy-radiation treatment

September 15, 2014
A study in mice implanted with breast and melanoma cancers adds to a growing body of evidence that highly focused radiation – long thought to suppress immunity – can actually help boost the immune system's fight against ...

Common cancers evade detection by silencing parts of immune system cells

March 4, 2014
Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most ...

Study finds potential predictive biomarker for response to PD-L1 checkpoint blocker

November 26, 2014
A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study ...

Triple therapy revs up immune system against common brain tumor

August 4, 2014
A triple therapy for glioblastoma, including two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report by scientists at the Johns ...

Immune therapy tested in study of women with triple-negative breast cancer

April 20, 2015
Early data in a preliminary human study show that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer, a persistently difficult form of the disease ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.